P
Pharming Group N.V. (PHGUF)
PNK – Real Time Price. Currency in USD
1.10
0.00 (0.00%)
Market open: Sep 8, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
PNK – Real Time Price. Currency in USD
1.10
0.00 (0.00%)
Market open: Sep 8, 2026, 4:00 PM EDT
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
| Name | Position |
|---|---|
| Dr. Alexander Breidenbach M.B.A., Ph.D. | Chief Business Officer |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer |
| Dr. Magnus Hansson | Medical Director |
| Mr. Fabrice Chouraqui M.B.A., Ph.D., Pharm.D. | CEO & Executive Director |
| Mr. Kenneth Lynard EMBA, M.Sc. | Chief Financial Officer |
| Mr. Michael K. Levitan | VP of Investor Relations & Corporate Communications |
There is no data to display
| Mr. Ruud Van Outersterp L.L.M. | Chief Legal & Compliance Officer and Company Secretary |
| Ms. Ines Bernal B.A. | Chief People Officer |
| Ms. Leverne Marsh BPHARM | Chief Commercial Officer |
| Ms. Mireille Sanders M.Sc. | Chief Operations Officer |